Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease
Retrieved on:
Monday, April 22, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, USD, Cirrhosis, Genomics, CLD, Liver disease, Boehringer Ingelheim, Chronic liver disease, Machine learning, The Gentle Touch, RNA, Partnership, Liver regeneration, Senior, Patient, Liver failure, DSM-IV codes, Disease, CRM, Boehringer, MASH, Outsourcing, Copper
Ochre Bio , a pioneer in chronic liver disease medicine development, today announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
Key Points:
- Ochre Bio , a pioneer in chronic liver disease medicine development, today announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
- Boehringer Ingelheim aims to develop new treatments modulating innovative regenerative targets with the potential to enhance the liver’s self-repair capabilities to prevent or reverse disease progression.
- It builds on Ochre Bio’s leading capabilities to leverage human data and disease models to accelerate the discovery and validation of novel liver disease targets.
- “Ochre Bio brings to the table unique and exciting capabilities in liver disease research.